The Nephron journals/Nephron journals· 2016Q2· Review
Should We STOP Angiotensin Converting Enzyme Inhibitors/Angiotensin Receptor Blockers in Advanced Kidney Disease?
- 11,736citations
- Q2SCImago
- 2016year
Short summary
The benefit of continuing ACE inhibitors (ACEi) or angiotensin II receptor blockers (ARBs) in advanced chronic kidney disease (CKD) with an estimated GFR (eGFR) below 30 ml/min/1.73 m2 remains uncertain, with no clear evidence of cardiovascular risk reduction in this population.
AI-generated from the title and abstract; the full text is not read.
TakeawaysIn the app
Key pointsIn the app
Ask the paperIn the app
The rest is in the Pofolia app
Takeaways, key points and questions to the paper; new summaries every day for your field. Free.
Sign in on the web to openField: Cardiology and Cardiovascular Medicine
Cardiology and Cardiovascular MedicineMedicine